AURA · Aura Biosciences, Inc.
$7.02
-0.03 (-0.43%)
At close · Jul 29
Going-concern doubt
— cleared May 11, 2026
The latest filing states the doubt was alleviated.
“As disclosed in the Company's audited consolidated financial statements as of and for the year ended December 31, 2025, events and conditions existed which raised substantial doubt about the Company's ability to continue as a going concern, primarily due to recurring operating losses, negative cash flows from operations and liquidity constraints. Subsequent to year end, the Company completed the 2026 Follow-On Offering, raising approximately $241.8 million in net proceeds after completion of the Matrix Repurchase. Based on the successful execution of this financing, management has concluded that the events and conditions that previously raised substantial doubt have been alleviated.”View the 10-Q filed May 11, 2026
Market Cap
$724.74M
Shares
103.39M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Key facts
CIK
1501796
CUSIP
05153U107
13F (30d)
18 filings
18 filers
Visit website
Investor relations